HASTINGS DAVID C — SEC Form 4 filings
SEC reporting owner CIK 1237401. 7 Form 4 filings on record with FilingPulse; latest filed 2026-06-30.
Transaction summary — filings shown
Covers all 7 filings on record, filed 2024-02-05 to 2026-06-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 31,776 shares, $95,011 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 11.
- Largest priced transaction: sale of 22,183 shares @ $3.28 ($72,827) in Arbutus Biopharma Corp, filed 2025-02-05.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | Chief Financial Officer | 3 | — | 2 legs · 31,776 sh · $95,011 | 4 |
| SCYNEXIS INC (SCYX) | Director | 3 | — | — | 6 |
| Trevi Therapeutics, Inc. (TRVI) | Chief Financial Officer | 1 | — | — | 1 |
Form 4 filings — HASTINGS DAVID C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-30 | 4 | SCYNEXIS INC (SCYX) | Grant/award (A): 2,875 @ $0 · Grant/award (A): 2,875 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | Trevi Therapeutics, Inc. (TRVI) | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2025-06-30 | 4 | SCYNEXIS INC (SCYX) | Grant/award (A): 23,000 @ $0 · Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Arbutus Biopharma Corp (ABUS) | Grant/award (A): 90,100 @ $0 · Grant/award (A): 365,800 (derivative) @ $0 | EDGAR |
| 2025-02-05 | 4 | Arbutus Biopharma Corp (ABUS) | Sale (S): 22,183 @ $3.28 | EDGAR |
| 2024-06-21 | 4 | SCYNEXIS INC (SCYX) | Grant/award (A): 23,000 @ $0 · Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-02-05 | 4 | Arbutus Biopharma Corp (ABUS) | Grant/award (A): 112,500 @ $0 · Sale (S): 9,593 @ $2.31 · Grant/award (A): 450,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1237401 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →